Navigation Links
Pharmacyclics Reports First Quarter 2013 Results
Date:5/1/2013

SUNNYVALE, Calif., May 1, 2013 /PRNewswire/ -- Pharmacyclics, Inc. (the "Company") (Nasdaq: PCYC) today reported financial results and recent developments for its three months ended March 31, 2013.

Financial Results for the Three Months Ended March 31, 2013 Non-GAAP net loss reported for the quarter ended March 31, 2013 was $28.3 million, or $0.40 loss per share compared to non-GAAP net loss of $9.3 million, or $0.14 loss per share for the quarter ended March 31, 2012.  See "Use of Non-GAAP Financial Measures" below for a description of our non-GAAP measures. Reconciliation between certain GAAP and non-GAAP measures is provided at the end of this press release.

As reported on April 11, 2013, the Company earned a $50 million milestone payment obligation under its collaboration and license agreement (the "Agreement") with Janssen Biotech, Inc. and its affiliates ("Janssen") as a result of the enrollment of a fifth patient in a study using ibrutinib (PCI-32765) as a monotherapy versus chlorambucil in elderly patients with newly diagnosed chronic lymphocytic lymphoma/small lymphocytic lymphoma. The $28.3 million non-GAAP net loss for the quarter ended March 31, 2013 did not include the $50 million milestone earned on April 11, 2013. The Company will record the above milestone as revenue for the quarter ending June 30, 2013. As such, the Company expects non-GAAP net income/loss to be near break-even for the quarter ending June 30, 2013 and also for the full year ending December 31, 2013. This includes the assumption of costs by Janssen in excess of the $50 million annual cap per calendar year ("Excess Amounts") under the Agreement with Janssen.

The generally accepted accounting principles ("GAAP") net loss for the quarter ended March 31, 2013 was $51.9 million, or $0.73 loss per share. This includes stock-based compensation expense of $23.6 million. For the quar
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related medicine technology :

1. Pharmacyclics Announces Date of Financial Results for Three Months Ended March 31, 2013 and Conference Call
2. Pharmacyclics Triggers Fourth Milestone Payment for Enrollment of 5th Patient in Frontline Phase III CLL Study
3. Pharmacyclics Announces Third Breakthrough Therapy Designation for Ibrutinib from the U.S. Food and Drug Administration
4. Pharmacyclics, Inc. Prices Public Offering of Common Stock
5. Pharmacyclics, Inc. Announces Proposed Public Offering of Common Stock
6. Pharmacyclics First to Announce Breakthrough Therapy Designation in Oncology from the U.S. Food and Drug Administration
7. Pharmacyclics Announces Date of Financial Results for Three and Six Months Ended December 31, 2012 and Conference Call
8. Pharmacyclics Reports Fourth Quarter and Full Year Fiscal 2012 Financial Results and Recent Developments
9. Pharmacyclics Announces Oral Presentations of Ibrutinib (PCI-32765) at the 17th Congress of the European Hematology Association
10. Pharmacyclics Announces Oral Presentations and Clinical Update of Ibrutinib (PCI-32765) at the 2012 Annual Meeting of the American Society of Clinical Oncology
11. Hospira Reports First-Quarter 2013 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... , May 22, 2015 AcelRx Pharmaceuticals, Inc. ... on the development and commercialization of innovative therapies for ... that interim chief executive officer Howie Rosen ... chief financial officer Tim Morris will be ... the two presentations are as follows: Jefferies ...
(Date:5/21/2015)... DUBLIN , May 21, 2015 ... has announced the addition of the "North ... & Graft), by Application (Surgical Wound, & Ulcer), ... Forecast to 2019" report to their offering. ... wound care market is estimated to grow at ...
(Date:5/21/2015)... , May 21, 2015  Cardica, Inc. (Nasdaq: CRDC ... Greg Watson , the company,s vice president of operations, ... company,s common stock, at a per share exercise price of ... stock option was granted pursuant to Cardica, Inc.,s Inducement Plan, ... May 2015 under Rule 5653(c)(4) of the Nasdaq Global Market ...
Breaking Medicine Technology:AcelRx Pharmaceuticals to Present at Two Upcoming Investor Conferences In June 2North American Active Wound Care Market 2015-2019 with Smith and Nephew, Molyncke HealthCare & ConvaTec Dominating 2Cardica Announces New Employment Inducement Grant 2
(Date:5/22/2015)... Philadelphia, PA (PRWEB) May 22, 2015 According ... as a hub for drug related death, totaling almost 2,500 ... number, as reported by state officials, totals 2,489 deaths stemming ... numbers work out, Pennsylvania loses seven people every day to ... Philadelphia has been singled out as one of the most ...
(Date:5/22/2015)... (PRWEB) May 22, 2015 Gateway Building ... exterior renovations. The services the company specialize in include ... remodeling, basements, pool houses and much more. , ... by the owner of the company. It includes two ... The design was thought out to be used with ...
(Date:5/22/2015)... sweetFrog Enterprises, LLC. is pleased to announce the ... now the 16th sweetFrog store located in the Lone Star ... on the Inc. 500 list of fastest growing companies in ... East Texas for 20 years and love the natural beauty ... and nearby Palestine, sweetFrog locations. “We are really excited about ...
(Date:5/22/2015)... Raton, FL (PRWEB) May 22, 2015 ... which provides vascular, electrocardiogram (EKG), echocardiogram and NCV ... David Sempier, a highly respected All American National athlete, ... multi-sport athlete, I find the high level of testing ... both the athlete and their athletic trainers, this way ...
(Date:5/22/2015)... Ticket Down is a reputable source for authentic ... Conference Finals Tickets . All seating for the 2015 ... ticket listing. , For the first time in some ... the Eastern Conference. One of the original franchises in the ... downs over the years, but the excitement level for this ...
Breaking Medicine News(10 mins):Health News:Philadelphia Ranks Among the Tops Cities in Penn. for Drug Deaths 2Health News:sweetFrog Opens New Location in Jacksonville, Texas 2Health News:Wimbledon Athletics Recruits Team USA Athlete 2Health News:Wimbledon Athletics Recruits Team USA Athlete 3Health News:Cheap Lightning vs Rangers NHL Eastern Conference Finals Tickets: Ticket Down Slashes Ticket Prices on New York Rangers vs Tampa Bay Lightning Eastern Conference Playoffs 2Health News:Cheap Lightning vs Rangers NHL Eastern Conference Finals Tickets: Ticket Down Slashes Ticket Prices on New York Rangers vs Tampa Bay Lightning Eastern Conference Playoffs 3
... ,Raised Without Antibiotics, ... ... third,largest poultry producer, has joined the Truthful Labeling Coalition (TLC),an industry ... all 50 states and other leading poultry companies,including Foster Farms, Gold,n ...
... say , , MONDAY, Dec. 10 (HealthDay News) -- Scientists ... called BRCA1 can cause some breast cancers. , Basal-like ... of all breast cancers. BBCs generally have a poor ... associated with hereditary mutations in the BRCA1 gene, the ...
... Neuropsychopharmacology Annual Meeting will feature hundreds of new ... leading scientists. Presentations include innovative research on ... autism and addiction. , SELECTED PANELS INCLUDE:, , ... A series of studies elucidates evidence that there ...
... /PRNewswire-FirstCall/ - Bradmer Pharmaceuticals Inc.,a biopharmaceutical company ... therapies, today announced that the start of,Company,s ... murine monoclonal,antibody radiolabeled with Iodine-131 (I-131), is ... from a nuclear facility in Chalk River,Ontario. ...
... the mechanisms that modulate the response of ovarian cancer ... in the December issue of Cancer Cell, helps to ... class of drugs and may lead to improved treatment ... undergo extensive microtubule-driven restructuring as they proliferate. Taxanes, such ...
... Zender, a senior clinical postdoctoral fellow at Cold Spring ... for his seminal contributions in the field of cancer ... annual Cracking the Code with the Bear Research Symposium, ... Zender studies the genetics and biology of hepatocellular carcinoma, ...
Cached Medicine News:Health News:Truthful Labeling Coalition Welcomes Perdue Farms 2Health News:Truthful Labeling Coalition Welcomes Perdue Farms 3Health News:Mutated Suppressor Gene Leads to a Type of Breast Cancer 2Health News:Mutated Suppressor Gene Leads to a Type of Breast Cancer 3Health News:New studies on cancer and schizophrenia, depression and heart disease, trauma and autism 2Health News:Bradmer Medical Isotope Supply For Phase III Trial Secure 2Health News:Bradmer Medical Isotope Supply For Phase III Trial Secure 3Health News:Extracellular protein sensitizes ovarian cancer cells to chemotherapy 2Health News:CSHL scientist recognized for accelerating cancer gene research 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: